Latest Headlines

  1. Graviton BioScience Announces Clearance Of Investigational New Drug (IND) For GV101 For The Treatment Of Friedreich's Ataxia 8/11/2026

    Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company developing a diverse pipeline of therapeutics, including selective ROCK2 inhibitors for metabolic, inflammatory, fibrotic, and central nervous system disorders, announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a novel capsule formulation of GV101, a proprietary oral ROCK2 inhibitor being developed for Friedreich's ataxia (FA).

  2. Bruker Announces Majority Investment In MIMETAS To Advance Human Physiology-Relevant Drug Discovery And Development 8/10/2026

    Bruker Corporation today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development.

  3. Lupin Announces The Approval Of Sodium Zirconium Cyclosilicate For Oral Suspension In The United States 8/10/2026

    Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet.

  4. Senhwa's CX-5461 Reaches Immuno-Oncology Milestone As Its First Multicenter Combination Trial With PD-1 Inhibitor Receives TFDA Clearance 8/6/2026

    Senhwa Biosciences, Inc. (TPEx: 6492) today announced that the Taiwan Food and Drug Administration (TFDA) has cleared the Company's multicenter Phase 1b/2a clinical trial evaluating its investigational drug pidnarulex (CX-5461) in combination with a marketed PD-1 immune checkpoint inhibitor.

  5. Ono Pharma Enters Into A Drug Discovery Partnership With Mediar Therapeutics To Create Novel Antibody Therapeutics For Fibro-Inflammatory Diseases 8/6/2026

    Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) announced today that it has entered into a drug discovery partnership and option agreement with Mediar Therapeutics, Inc.

  6. Greenstone Biosciences Receives NIH R61 Grant To Advance Cardiac Fibrosis Therapeutics For Duchenne Muscular Dystrophy 8/6/2026

    Greenstone Biosciences, a biotechnology company advancing New Approach Methodologies (NAMs) for drug discovery, today announced that it has received a Catalyze R61 award from the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH).

  7. Clarivate Scales Agentic AI Across Cortellis To Advance Drug Development 8/6/2026

    Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the expansion of agentic AI capabilities across the Cortellis portfolio, helping life sciences R&D teams accelerate discovery, strengthen safety assessment and make faster, more informed portfolio decisions.

  8. Schrödinger Announces Strategic Collaboration And Software Agreement With Bristol Myers Squibb To Deploy AI Co-Scientist Bunsen For Agentic Drug Discovery 8/5/2026

    Schrödinger, Inc. today announced a strategic agreement with Bristol Myers Squibb (BMS) to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization.

  9. AI-Empowered Pipeline-In-A-Drug Option: Insilico Medicine Nominates ISM9077, Potential First-In-Class Target Y Inhibitor, As Preclinical Candidate (PCC) For Ocular Diseases, Inflammatory Disorders And Aging 8/5/2026

    Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM9077, the AI-empowered, potential first-in-class Target Y inhibitor with pipeline-in-a-drug potential, as a Preclinical Candidate (PCC) for the treatment of ocular diseases including dry Age-Related Macular Degeneration (dry AMD), uveitis, and dry eye disease.

  10. IQVIA And Medera To Advance Cardiac Gene Therapy And Human-Based Drug Discovery 8/4/2026

    IQVIA, a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company pioneering next-generation therapeutics for cardiovascular disease, today announced a strategic collaboration to accelerate the development of cardiac gene therapies and human-based drug discovery platforms.